Tuesday, 17 Nov 2026 Breaking: Iran rejects reports of "dirty bomb" plot against Trump officials; Araghchi calls reports "rubbish"
BREAKING: Apple launches AI platform | Tesla earnings beat estimates | Nvidia stock surges | Bitcoin crosses major resistance
Business

Sahajanand Medical Technologies Secures Regulatory Approval in Egypt for Supraflex Cruz Coronary Stent

Sahajanand Medical Technologies Secures Regulatory Approval in Egypt for Supraflex Cruz Coronary Stent

NewsVoir
Mumbai (Maharashtra) [India], September 16: Sahajanand Medical Technologies (SMT) has received regulatory approval from the Egyptian Drug Authority (EDA), Central Administration of Medical Devices, for its Supraflex Cruz Sirolimus Eluting Stent System, marking the company’s entry into a new market in Africa. This EDA approval gives physicians in Egypt access to the Supraflex Cruz platform and strengthens SMT’s broader expansion strategy in new markets.
According to World Health Organization data, ischaemic heart disease was the leading cause of death in Egypt in 2021, underscoring the country’s substantial cardiovascular disease burden.¹ By making SupraFlex Cruz available to Egyptian interventional cardiologists, SMT is expanding access to its clinically evaluated, coronary stent platform. This milestone also advances SMT’s commitment to improving access to cardiovascular care and saving lives.
“Egypt is an important addition to SMT’s international footprint and strengthens our presence in Africa. Expanding access to our coronary technologies in this market advances our commitment to supporting physicians, improving cardiovascular care and saving more lives around the world,” said Anil Suri, Chief Commercial Officer, at Sahajanand Medical Technologies.
At the TCT 2025, SMT reported findings from the TUXEDO-II and Multivessel TALENT trials. In TUXEDO-II, the one-year target-lesion-failure outcome for Supraflex Cruz was comparable with a contemporary, market-leading everolimus-eluting stent comparator. In Multivessel TALENT, Supraflex Cruz met the prespecified non-inferiority endpoint for the 12-month patient-oriented composite outcome when compared to an industry-standard contemporary drug-eluting control stent.
About Supraflex Cruz
Supraflex Cruz DES belongs to the Supraflex family of stents, which, through a series of clinical trials including the TALENT trial and has demonstrated safety and effectiveness comparable to the drug-eluting stents evaluated in these trials.
About SMT (Sahajanand Medical Technologies)
SMT (Sahajanand Medical Technologies Limited) is a medical devices company with a portfolio of technologically advanced medical devices across vascular and structural heart intervention. SMT offers an extensive portfolio of products focusing on vascular intervention and was the first company in the world to receive CE certification for a DES with a biodegradable polymer. SMT has a global presence, exporting products to more than 75 countries, as on March 31, 2025.
For further updates, please the website or follow SMT on LinkedIn.
Disclaimer
Sahajanand Medical Technologies Limited is proposing, subject to receipt of requisite approvals, market conditions and other considerations, an initial public offer of its equity shares and has filed a draft red herring prospectus dated July 25, 2025 (“DRHP”) with the Securities and Exchange Board of India (“SEBI”) and the stock exchanges. The DRHP is available on our website at www.smtpl.com as well as on the website of SEBI at www.sebi.gov.in, Motilal Oswal Investment Advisors Limited at www.motilaloswalgroup.com, Avendus Capital Private Limited at www.avendus.com, HSBC  Securities  and  Capital Markets (India) Private Limited at www.business.hsbc.co.in and Nuvama Wealth Management Limited at www.nuvama.com and and the websites of the stock exchange(s) at www.nseindia.com and www.bseindia.com, respectively. Any potential investor should note that investment in equity shares involves a high degree of risk and refer to the Red Herring Prospectus, including the section titled “Risk Factors” of the Red Herring Prospectus when available, for details. Potential investors should not rely on the DRHP for any investment decision.
References
1. data.who.int/countries/818
(ADVERTORIAL DISCLAIMER: The above press release has been provided by NewsVoir. ANI will not be responsible in any way for the content of the same)

Tags

Related News

"India is the most interesting market": Italian industry leaders seek joint ventures and MRO expansion after talks with Piyush Goyal
Business
"India is the most interesting market": Italian industry leaders seek joint ventures and MRO expansion after talks with Piyush Goyal

<p>Rome [Italy], November 17 (ANI): Leading Italian companies across aviation maintenance, medical imaging, construction...

Jensen Huang signals willingness to return as Nvidia CEO: Report
Business
Jensen Huang signals willingness to return as Nvidia CEO: Report

<p>Santa Clara (California) [US], November 17 (ANI): Wall Street Journal on Tuesday reported that embattled former Nvidi...

China threatens countermeasures against US restrictions on advanced semiconductor access
Business
China threatens countermeasures against US restrictions on advanced semiconductor access

<p>Beijing [China], November 17 (ANI): China on Tuesday strongly opposed the United States' latest restrictions on remot...

"American people need answers": House Committee Chairmen welcome Jensen Huang's acceptance to testify
Business
"American people need answers": House Committee Chairmen welcome Jensen Huang's acceptance to testify

<p>Washington DC [US], November 17 (ANI): Chairmen Mast, Moolenaar, and Crawford released a statement after Jensen Huang...

Israel to launch 'Landing Pad' programme to help its companies find Indian partners: Ambassador Reuven Azar
Business
Israel to launch 'Landing Pad' programme to help its companies find Indian partners: Ambassador Reuven Azar

<p>Bengaluru (Karnataka) [India], November 17 (ANI): Israel will launch a new programme called 'Landing Pad' to help Isr...

Jensen Huang to appear before US House committees on December 1
Business
Jensen Huang to appear before US House committees on December 1

<p>Washington DC [US], November 17 (ANI): Former Nvidia CEO Jensen Huang will appear before the House Foreign Affairs, I...